Rigel Pharmaceuticals Inc (NASDAQ:RIGL)
| 1.10 BATS BZX Real-Time Price As of 3:18pm ET |  +0.05 / +4.76%Today’s Change | 0.67 Today|||52-Week Range 2.04 | -26.67% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $167.3M |
Company Description
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Contact Information
Rigel Pharmaceuticals, Inc. 611 Gateway Boulevard South San Francisco California 94080-1985 |
Employees
Shareholders
| Other institutional | 41.71% |
| Mutual fund holders | 20.51% |
| Individual stakeholders | 12.38% |
Top Executives
| Raul R. Rodriguez | President, Chief Executive Officer & Director |
| Dean L. Schorno | Chief Financial Officer & Executive Vice President |
| Esteban S. Masuda | Executive Vice President-Research |
| David A. Santos | Chief Commercial Officer & Executive VP |
| Raymond J. Furey | Secretary, Executive VP & General Counsel |
